Skip to main content
Premium Trial:

Request an Annual Quote

CPGR, SimuGen Enter Into Biomarker Assay Pact

NEW YORK (GenomeWeb News) – South Africa's Centre for Proteomic and Genomic Research today said that it has entered into an agreement with SimuGen to develop biomarker assays for the prediction of toxicity of existing and new drug compounds.

SimuGen is a Malaysia-based pharmacogenomics firm working on novel dose-toxicity models for drug development customers.

"The work we will do with Simugen, aimed at improving the ability to develop novel, safe drugs, fits perfectly into our vision of creating cutting-edge ex-vivo drug screening workflows that make full use of our genomic and proteomic platforms," Reinhard Hiller, managing director of CPGR, said in a statement.

CPGR was founded in 2006 as a non-profit organization to provide South African scientists with analytical services, project support, and collaborative research capabilities in the genomics and proteomics fields. The organization has a particular interest in translational research and has branched out into molecular diagnostics and drug discovery.

Terms of the collaboration with SimuGen were not disclosed.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.